EBITDA: Income before interest, taxes, depreciation and amortization.
Traws Pharma, Inc. (TRAW) had EBITDA of $-17.81M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.79M |
|
$6.87M |
|
-- |
|
$2.79M |
|
$20.66M |
|
$-17.88M |
|
$27.05M |
|
$9.17M |
|
$9.17M |
|
$9.17M |
|
$9.17M |
|
$9.17M |
|
$9.17M |
|
$-17.88M |
|
|
EBITDA |
$-17.81M |
8.23M |
|
8.38M |
|
$0.83 |
|
$0.82 |
|
| Balance Sheet Financials | |
$7.98M |
|
$0.01M |
|
$2.64M |
|
$10.62M |
|
$11.15M |
|
-- |
|
$0.10M |
|
$11.25M |
|
$-0.63M |
|
$-3.16M |
|
$-0.63M |
|
9.07M |
|
| Cash Flow Statement Financials | |
$-18.18M |
|
$-2.58M |
|
$3.20M |
|
$21.34M |
|
$3.82M |
|
$-17.52M |
|
$0.73M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-640.68% |
|
-640.68% |
|
-638.49% |
|
328.67% |
|
246.06% |
|
$-18.18M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
-- |
|
0.74 |
|
496.35 |
|
-1457.85% |
|
-290.56% |
|
86.37% |
|
-1457.87% |
|
$-0.07 |
|
$-2.17 |
|
$-2.17 |
|